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Background: Although advances in HIV medicine have yielded increasingly better treatment outcomes in recent
years, HIV-positive people with access to antiretroviral therapy (ART) still face complex health challenges. The
EuroSIDA Study Group surveyed its clinics to explore regional differences in clinic services.
Methods: The EuroSIDA study is a prospective observational cohort study that began enrolling patients in 1994. In
early 2014, we conducted a 59-item survey of the 98 then-active EuroSIDA clinics. The survey covered HIV clinical
care and other aspects of patient care. The EuroSIDA East Europe study region (Belarus, Estonia, Lithuania, the
Russian Federation and Ukraine) was compared to a “non-East Europe” study region comprised of all other
EuroSIDA countries.
Results: A larger proportion of clinics in the East Europe group reported deferring ART in asymptomatic patients
until the CD4 cell count dropped below 350 cells/mm3 (75 % versus 25 %, p = 0.0032). Considerably smaller
proportions of East Europe clinics reported that resistance testing was provided before ART initiation (17 % versus
86 %, p < 0.0001) and that it was provided upon treatment failure (58 % versus 90 %, p = 0.0040). Only 33 % of East
Europe clinics reported providing hepatitis B vaccination, compared to 88 % of other clinics (p < 0.0001). Only 50 %
of East Europe clinics reported having access to direct-acting antivirals for hepatitis C treatment, compared to 89 %
of other clinics (p = 0.0036). There was significantly less tuberculosis/HIV treatment integration in the East Europe
group (27 % versus 84 % p < 0.0001) as well as significantly less screening for cardiovascular disease (58 % versus
90 %, p = 0.014); tobacco use (50 % versus 93 %, p < 0.0001); alcohol consumption (50 % versus 93 %, p < 0.0001);
and drug use (58 % versus 87 %, p = 0.029).
Conclusions: Study findings demonstrate how specific features of HIV clinics differ across Europe. Significantly
more East Europe clinics deferred ART in asymptomatic patients for longer, and significantly fewer East Europe
clinics provided resistance testing before initiating ART or upon ART failure. The East Europe group of clinics also
differed in regard to hepatitis B vaccination, direct-acting antiviral access, tuberculosis/HIV treatment integration and
screening for other health issues. There is a need for further research to guide setting-specific decision-making
regarding the optimal array of services at HIV clinics in Europe and worldwide.
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Advances in HIV medicine have yielded increasingly bet-
ter treatment outcomes in recent years, in part because
people living with HIV (PHLIV) are now offered more
effective and more tolerable antiretroviral therapy (ART)
regimens with simpler dosing schedules [1]. Life expect-
ancy has increased greatly for ART-treated PLHIV, and
may even be approaching life expectancy in the general
population [2, 3]. Nonetheless, HIV remains a major
health threat; there were 136,235 new HIV infections
reported in the World Health Organization (WHO)
European Region in 2013 [4], and HIV was estimated to
be the sixth-leading cause of death worldwide in 2010 [5].
Although deaths from HIV are concentrated in
resource-limited countries in sub-Saharan Africa and
Southeast Asia [6], the disease also continues to claim lives
in regions with high levels of treatment coverage. For ex-
ample, France, Italy and Spain all were estimated to have
more than 1000 HIV-related deaths in 2013 [7]. At the
same time, non-HIV-related conditions are emerging as
prominent health concerns in settings where ART is widely
available. A large body of evidence indicates that HIV-
positive people are at above-average risk for cardiovascular
disease [8] and various non-AIDS-defining cancers [9]. A
prospective cohort study of 5185 Spanish PLHIV found
that the most common non-AIDS events were psychiatric,
liver, kidney, cardiovascular and cancer-related events [10].
This situation raises the question of how the health
needs of PLHIV should be addressed beyond the
provision of antiretroviral therapy. The global discourse
around the response to HIV has emphasised the import-
ance of addressing treatment access barriers such as
drug costs, health worker shortages, and laws and pol-
icies that discourage marginalised populations from
seeking HIV services. Merely having access to ART,
however, does not in itself ensure that a person living
with HIV will enjoy optimal health outcomes. Following
the initiation of ART, virological failure may result from
poor adherence, drug resistance, drug toxicity or other
factors [11]. Furthermore, achieving viral suppression does
not always result in the restoration of the immune system.
Additionally, even in settings where ART is widely
available, a multitude of social and institutional factors
may influence people’s willingness and ability to adhere
to treatment and remain engaged in clinical care. In
Valencia, Spain, for example, people who inject drugs
(PWID) identified their ongoing drug use as a barrier to
adhering fully to ART and reported that a lack of social
support hindered adherence as well [12]. In a cohort of
African-American men taking ART, adherence was found
to be lower among men who experienced stigmatizing at-
titudes about HIV from members of their social networks
[13]. A study of barriers to accessing care among HIV-
positive women in 27 countries found that major barriersfor women in European countries and Canada included
community HIV stigma, lack of employment opportunities
and lack of supportive work environments [14].
In light of the array of concerns about the health of
HIV-positive people with access to treatment, the
EuroSIDA Study Group is exploring whether there are re-
gional differences in health outcomes among its partici-
pating clinics and what some of the underlying causes of
such differences might be. EuroSIDA has presented evi-
dence of variability across different regions of Europe in
initial virologic response to ART [15] and the likelihood of
maintaining viral suppression on ART [16], as well as in
AIDS-related and non-AIDS-related mortality [17].
Poorer outcomes for the EuroSIDA East Europe study re-
gion could not be explained by differences in demographic
or HIV-related factors for which we were able to adjust.
These observations led researchers to consider the
possible role of factors at the service delivery level. As a
preliminary step in pursuing this line of inquiry, we con-
ducted a survey to see whether regional differences
could be identified in EuroSIDA clinics in regard to nu-
merous aspects of service provision. The following study
presents findings from the first EuroSIDA clinic survey.
Methods
The EuroSIDA study is a prospective observational cohort
study that began enrolling patients in 1994. Details of the
study have been published previously [18]. EuroSIDA fol-
lows more than 18,000 HIV-positive patients at 108 clinics
in 35 European countries, Israel and Argentina. EuroSIDA
clinics collect demographic and clinical data from study
participants at six-month intervals under the direction of
the study coordinating centre, which is based at CHIP, the
Centre for Health and Infectious Disease Research
(Rigshospitalet, Copenhagen, Denmark). Data collected in-
clude CD4 and viral load levels as well as details about
antiretroviral (ART) usage, AIDS-defining illnesses, and
selected non-AIDS defining clinical events. All study sites
have met national ethical requirements and received ap-
proval in the countries in which they are located.
In early 2014, our study team conducted a survey of
the 97 then-active EuroSIDA clinics (excluding clinics in
Argentina). The principal investigator at each EuroSIDA
clinic was invited to voluntarily complete the survey.
(Principal investigators are medical doctors who are cen-
trally involved with the treatment and management of
HIV patients seen at the clinic.) We did not request in-
formed consent from survey respondents because the
survey did not ask for identifiable private information
about the respondents or any other individuals. The
three main sections of the survey asked respondents to
answer a total of 59 questions: 31 about clinic and pa-
tient characteristics; 22 about HIV clinical care and care
of other infectious diseases; and six about non-HIV
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with multiple-choice answers. (The survey is available at
www.chip.dk/eurosida/csurvey and in Additional file 1)
Content, construct and face validity of the survey were
ensured by piloting it in three countries and consulting
experts in the field, including the 15 members of the
EuroSIDA steering committee. Data were collected and
managed through Research Electronic Data Capture
(REDcap; http://project-redcap.org), which was hosted at
Rigshospitalet. Participants were emailed multiple times,
and were called if there was no response.
To inform our understanding of the generalisability of
survey findings to the EuroSIDA network as a whole,
characteristics of EuroSIDA patients from clinics partici-
pating in the survey were compared with characteristics
of EuroSIDA patients from non-participating clinics. We
included patients from the network if they had been
followed up after 1 January 2012, were aged >16 and had
undergone CD4 count and viral load testing within
12 months of baseline. Characteristics of persons were
summarised using simple summary statistics. Characteris-
tics of persons at participating and non-participating clinics
were compared using Wilcoxon signed rank test for con-
tinuous variables and chi-squared tests or Fisher’s exact
tests when numbers were small for categorical variables.
Previous research has shown EuroSIDA patient out-
comes in the South, North and Central Western Europe
study regions to be quite similar [16]. Therefore these
regions were combined with all other countries apart
from the five EuroSIDA East Europe countries to create
a “non-East Europe” study region, which then was com-
pared to East Europe (Belarus, Estonia, Lithuania, the
Russian Federation and Ukraine) (Table 1). Responses to
the clinic survey from these two study regions wereTable 1 Countries with EuroSIDA clinics participating in the
clinic survey
East Europe study region
Belarus Lithuania Ukraine
Estonia Russian Federation
Non-East Europe study region
North
Europe




Denmark Greece Austria Croatia
Finland Israel Belgium Czech Republic
Iceland Italy France Hungary
Ireland Portugal Germany Poland
Netherlands Spain Luxembourg Romania
Norway Switzerland Serbia
Sweden Slovenia
United Kingdomcompared using simple summary statistics and Wilcoxon
signed rank test for continuous variables, while categor-
ical variables were compared using chi-squared tests or
Fisher’s exact tests when numbers were small.
All statistical analyses were performed using SAS
(Statistical Analysis Software, Cary, NC, USA) version
9.3. A p-value of <0.05 was considered statistically sig-
nificant and all reported tests were 2-sided.
Findings are organised into the following topics in the re-
sults section of this paper. After an overview of responding
clinics and clinic patients, regional comparisons of survey
responses are presented in relation to HIV management,
the management of major co-infections, other components
of clinical management, and non-clinical support services.
Results
Responding clinics and clinic patients
Among 97 currently active EuroSIDA clinics in 35 coun-
tries, 81 clinics in 31 countries completed the survey for
a response rate of 83.5 %. Most of the responding clinics
in the five East Europe countries were government
clinics (92 %), while most of the responding clinics in
the other countries were university clinics (62 %). Eighty
of 81 responding clinics were in urban settings. The me-
dian year of the clinic’s establishment was more recent
for clinics in the East than clinics in the non-East (1992
[N = 12] versus 1985 [N = 66]; p < 0.0001). Clinics in the
East (N = 12) reported seeing a median of 2250 HIV-
positive patients while clinics in the non-East (N = 61)
reported seeing a median of 1234 HIV-positive patients,
but this difference was not statistically significant.
Two statistically significant differences were found be-
tween patient populations at EuroSIDA clinics that
responded to the survey and EuroSIDA clinics that did not.
Clinics that included more patients into the EuroSIDA co-
hort were less likely to be non-responders to the survey
(adjusted odds ratio [aOR] 0.61 per 50 additional patients,
95 % confidence interval [CI] 0.34–1.08, p = 0.091). Clinics
with a higher proportion of persons with a prior AIDS diag-
nosis were more likely to be non-responders (aOR 1.45/
10 % higher; 95 % CI 0.97–2.18, p = 0.070).
HIV management
A larger proportion of East than non-East clinics re-
ported following the World Health Organization’s HIV
treatment guidelines (50 % versus 7 %, p < 0.0001)
(Fig. 1). At the same time, a smaller proportion of East
Europe clinics reported following the European AIDS
Clinical Society’s HIV treatment guidelines in compari-
son to non-East clinics (42 % versus 77 %, p = 0.032). A
larger proportion of clinics in the East Europe group re-
ported deferring antiretroviral therapy in asymptomatic
patients until the CD4 cell count dropped below 350
cells/mm3 (75 % versus 25 %, p = 0.0032). Two other
Fig. 1 Regional differences in ART treatment and management. (1) data available for N = 79, 12 from East Europe and 67 from non-East Europe
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East clinics related to resistance testing, with consider-
ably smaller proportions of East Europe clinics reporting
that resistance testing was provided before the initiation
of ART (17 % versus 86 %, p < 0.0001) and that it
was provided upon treatment failure (58 % versus
90 %, p = 0.0040).
Management of major co-infections
The East Europe clinic group and non-East group both
reported high levels of routine screening for hepatitis B
virus (HBV) and hepatitis C virus (HCV) (Fig. 2). Only
33 % of East Europe clinics reported providing some
level of hepatitis B vaccination, compared to 88 % of
other clinics (p < 0.0001). Only 50 % of East Europe
clinics reported having access to direct-acting antivirals
(DAAs) for hepatitis C treatment, compared to 89 % of
other clinics (p = 0.0036).
Similar proportions of clinics in the East and non-East
groups reported performing tuberculosis (TB) screening
(58 % versus 62 %, p = 0.89) (Fig. 3). A much smaller
proportion of East clinics reported that HIV patients di-
agnosed with TB received TB treatment integrated into
HIV care and treatment (27 % versus 84 %, p < 0.0001).
Correspondingly, more East Europe clinics reported re-
ferring patients with TB to affiliated services for TBtreatment (64 % versus 12 %, p < 0.0001). One clinic in
East Europe reported not providing TB treatment
through either of these channels.
Other components of clinical management
Clinics in the East and non-East groups reported having
similarly high levels of routine screening for haematol-
ogy, liver function and renal function (Fig. 4). There
were lower levels of four other forms of screening: anal
pap test, anorectal exam, cervical smear and gynaeco-
logical exam. The East Europe group lagged behind the
non-East group on all four forms of screening, but these
differences were not statistically significant.
There was significantly less screening in East Europe for
four health issues: cardiovascular disease (58 % versus 90 %,
p = 0.014); tobacco use (50 % versus 93 %, p < 0.0001); alco-
hol consumption (50 % versus 93 %, p < 0.0001); and drug
use (58 % versus 87 %, p = 0.029).
Non-clinical support services
A diverse array of survey items was used to assess the
provision of non-clinical support services (Fig. 5). Drug/
alcohol treatment services and opioid substitution ther-
apy were not reported to be available at many clinics ei-
ther within or outside of East Europe. Although lower
proportions of East Europe clinics provided both types
Fig. 3 Regional differences in management of tuberculosis. (1) data available for N = 78, 11 from East Europe and 67 from non-East Europe
Fig. 2 Regional differences in management of hepatitis B and hepatitis C. *including yes and sometimes. (1) data available for N = 78, 12 from
East Europe and 66 from non-East Europe
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Fig. 4 Regional differences in routine screening for other health issues. (1) data available for N = 76, 12 from East Europe and 64 from non-East
Europe. (2) data available for N = 78, 12 from East Europe and 66 from non-East Europe. (3) data available for N = 80, 12 from East Europe and 68
from non-East Europe
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cant. East Europe clinics also reported non-significantly
lower levels of HIV disclosure counselling and staff
training for HIV disclosure counselling. High propor-
tions of clinics in both the East and non-East groups
were found to have on-site pharmacies while low pro-
portions were found to provide childcare.
Three statistically significant differences were found
for non-clinical support services. Eighty-three percent of
clinics in East Europe countries reported having loss-to-
follow-up levels exceeding 5 % among their HIV-positive
patients in the preceding 12 months, compared to 24 %
of clinics with greater than 5 % loss-to-follow-up in
other countries (p < 0.0001). Also, East Europe clinics
had lower levels of mental health treatment and/or
referral (42 % versus 74 %, p = 0.040) as well as lower
levels of family planning counselling (33 % versus
68 %, p = 0.048).
Discussion
To our knowledge this is the first large-scale study to
compare HIV clinics located in different areas of Europe
in terms of a wide range of service delivery features. We
chose to compare EuroSIDA study clinics in a group of
five countries – Belarus, Estonia, Lithuania, the Russian
Federation and Ukraine – to EuroSIDA study clinics
elsewhere in Europe because of previous findings of
poorer health outcomes for study participants in this re-
gion [15–17]. Our findings are consistent with thehypothesis that some clinic characteristics may influence
patient outcomes. There were marked differences in how
the East Europe group of clinics handled issues such as
the initiation of ART in asymptomatic patients and the
provision of resistance testing. Furthermore, the East
Europe clinics as a whole had a smaller array of services
relating to some aspects of viral hepatitis control, tubercu-
losis control and screening for other health issues.
At the time the clinic survey was conducted, World
Health Organization treatment guidelines indicated that
ART should always be initiated in HIV-positive people
when CD4 cell count levels dropped below 500 cells/
mm3 [19], while European AIDS Clinical Society guide-
lines recommended using a lower CD4 threshold of 350
cells/mm3 [11]. The clinic survey revealed that at a sig-
nificantly larger proportion of clinics in East Europe
than elsewhere, it was standard practice to delay ART
until the CD4 level was below 350 cells/mm3. In light of
what is now known about early ART initiation having an
important protective effect on the immune system, it is
reasonable to speculate that having a lower CD4 thresh-
old for initiating ART in asymptomatic patients at East
Europe clinics may have contributed to poorer patient
outcomes. Patients’ health also may have suffered be-
cause of a lack of resistance testing, which was provided
by smaller proportions of East Europe clinics both be-
fore the initiation of ART and upon treatment failure.
Chronic hepatitis B and hepatitis C disease both have
emerged as major health issues for people living with
Fig. 5 Regional differences in non-clinical support services. (1) data available for N = 80, 12 from East Europe and 68 from non-East Europe. (2)
data available for N = 79, 11 from East Europe and 68 from non-East Europe. (3) data available for N = 76, 11 from East Europe and 65 from non-East
Europe. (4) data available for N = 80, 12 from East Europe and 68 from non-East Europe. (A) Of 27 clinics answering yes, the median % LTFU was 15
(IQR 12–20) in East Europe and 10 (IQR 8–11) in non-East Europe; p = 0.021
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for all three diseases accounting for high levels of HIV/
HBV coinfection and HIV/HCV coinfection in some
populations [20]. In our study, only half of clinics in the
East Europe group had access to direct-acting antivirals
for hepatitis C treatment, compared to 86 % of clinics
elsewhere. DAAs stand apart from earlier generations of
HCV treatment for their high cure rates, and the price
of the newest, most effective DAAs has raised
widespread concern about financial inaccessibility for
patients in resource-limited settings and even in resource-
rich settings [21, 22]. It is not known whether a lower
proportion of EuroSIDA East Europe clinics reported hav-
ing access to DAAs because of their high cost or for other
reasons, but cost seems likely to be a factor as well as pa-
tient selection, with many in need being people who inject
drugs [23]. The finding points to a need to further investi-
gate differential use of DAAs in HIV/HCV co-infected
populations across countries as a step toward determining
how liver-related morbidity and mortality in these popula-
tions can be reduced.
Study findings for TB screening raise concerns for the
entire European region, with fewer than two-thirds ofclinics in either study group reporting screening. TB is
one of the most common AIDS-indicative diseases diag-
nosed in the WHO European Region [4], and HIV clin-
ical protocols for the WHO European Region call for all
PLHIV to be screened for TB [24]. Fairly large propor-
tions of EuroSIDA clinics in both East Europe and non-
East Europe countries appear to not be implementing
this guideline. It is possible that the consequences are
more pronounced in the East Europe countries, given
the high burden of TB and multidrug-resistant TB in
those countries [25]. The low level of integration of TB
treatment into HIV care and treatment in the East
Europe study region – with only 22 % of clinics report-
ing this to be the case – raises serious concerns in light
of what is known about the benefits of an integrated
clinical approach to TB/HIV co-infection [26].
The East Europe clinics lagged behind other clinics in
regard to screening for cardiovascular disease, tobacco
use, alcohol consumption and drug use, all issues with
important implications for PLHIV. Cardiovascular dis-
ease is a major cause of non-HIV-related mortality in
PLHIV populations [27, 28], and people who smoke to-
bacco have an elevated risk of cardiovascular disease
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the liver of HBV, HCV and other liver diseases [30], as
well as potentially having other negative health effects
[31, 32]. While screening for drug use is considered a
good practice in many clinical settings, it warrants spe-
cial consideration in settings where a major pathway for
HIV transmission is injecting drug use. This is the case
in the East Europe EuroSIDA clinics, with 38 % of the
1370 East Europe study participants who contributed
data to this study reporting injecting drug use as their
mode of exposure to HIV. In this context, the reported
absence of routine screening for drug use at 42 % of East
Europe clinics stands out as an issue that may have im-
portant implications for patients’ health.
Taken together, our study findings raise important
questions regarding whether the availability of a range of
services at clinics caring for PLHIV might have an im-
pact on morbidity and mortality. At a time when anti-
retroviral therapy is widely available in high-income
countries and is becoming increasingly available in low-
and middle-income countries, these questions are im-
portant to take up since they reflect a growing awareness
that antiretroviral therapy alone is not sufficient to safe-
guard the long-term health of PLHIV. Surprisingly, in
light of the advanced state of HIV management in some
regards, there appears to not be a large evidence base re-
garding which services a clinic should provide to its
HIV-positive patients. The comprehensive HIV care
model, with a healthcare team coordinating primary
care, HIV care, and other specialist care as well as psy-
chosocial and social services, has long been championed
in the United States [33] and has likely influenced the
development of many multifaceted HIV clinical initia-
tives worldwide. However, there is scant evidence re-
garding the relationship between specific HIV clinic
characteristics and patient health outcomes.
A 2006 Cochrane review of studies that assessed vari-
ous elements of the “setting and organisation of care”
for PLHIV found an association between case manage-
ment and decreased mortality, but concluded that the
small evidence base in this field was not sufficient to de-
termine an ideal set of clinic characteristics [34]. Since
the publication of the Cochrane review, little new evidence
has emerged. A 2009 retrospective cohort study of PLHIV
at health facilities for US military veterans found that pa-
tients attending clinics that integrated hepatitis, psychi-
atric, psychological and social services into HIV clinical
management were more than three times as likely to
achieve viral suppression on ART than patients attending
HIV clinics without integrated services [35].
A key challenge in conceptualising and conducting
meaningful research in this domain is the setting-
specific nature of how health services are organised,
funded, managed and governed. For example, the issueof whether or how to integrate HIV clinical services with
other clinical services has been highlighted particularly
in the context of efforts to provide HIV care in severely
resource-constrained settings, with studies in sub-
Saharan Africa and elsewhere examining different ser-
vice delivery models [36] and undertaking different
forms of service integration in order to provide HIV ser-
vices alongside other services such as tuberculosis man-
agement [37] and reproductive health care [38]. This
research may be of limited value to health system
decision-makers in settings with much higher physician-
patient ratios or with strong referral systems linking
long-established HIV clinics to other services. Clearly
there are major differences in regard to which health
service delivery models are predominant in different
countries, with some differences largely attributable to
resource limitations in poorer countries.
Nonetheless, the identification of key elements of suc-
cessful patient management in diverse settings presents
opportunities to explore ways in which these elements
may or may not be uniquely dependent on specific fea-
tures of the local and national health system and the so-
cial, political and economic context. It is entirely
possible that some service delivery innovations in sub-
Saharan Africa may be relevant to health systems in
Western Europe, and vice versa. By calling attention to
ways in which two regional groupings of clinics for
PLHIV in Europe differ from each other, the EuroSIDA
clinic survey findings serve as an invitation for clinics
and regions with suboptimal patient outcomes to inves-
tigate whether the adoption of practices from other set-
tings may be beneficial. Thus the lack of generalisability
of a study of the characteristics of health service delivery
in a specific group of clinics may be offset by its poten-
tial to highlight issues warranting further setting-specific
research including operational research on service deliv-
ery modifications in “real world” clinic populations.
In sum, our study makes a unique contribution to the
issue of HIV management by exploring whether the
characteristics of clinics vary across two groups of
European countries that have had marked differences in
patient outcomes in a large observational study cohort.
The identification of some statistically significant differ-
ences in clinic characteristics cannot be interpreted as
evidence that one or more of those differences is causing
the observed differences in patient outcomes. However,
findings suggest that it may be beneficial to conduct fur-
ther research on the potential health impact of clinic
characteristics such as the CD4 threshold for ART initi-
ation; ART resistance testing practices; HCV treatment
standards; and the provision of screening for non-HIV-
related conditions including alcohol and drug depend-
ency. Policy-makers should consider research on service
delivery factors alongside other types of research on
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ence of the social, political and economic context in
order to optimally configure health care for PLHIV at
the national and subnational levels.
Limitations
This study has the following limitations. While our sur-
vey addressed major aspects of the clinical and non-
clinical care of people living with HIV, there may be
other aspects of patient care that have implications for
patient outcomes. The study utilises survey data that
were reported by clinic representatives whose responses
to questions might not reflect what actually happens in
clinical practice. Clinical decision-making about some of
the issues addressed in our study can be expected to
vary in accordance with individual physicians’ prefer-
ences as well as patient characteristics such as the nature
of symptoms and severity of disease. Furthermore, study
findings reflect self-reporting, and it is not possible to verify
the accuracy of the information reported. Respondents may
have made errors or altered their responses to suggest a
higher level of compliance with guidelines. The survey was
conducted in English, which may have affected how ques-
tions were interpreted by some respondents. Findings have
limited generalisability because the EuroSIDA clinics con-
stitute only a small proportion of HIV clinics in European
countries. Generalisability is also affected by key character-
istics of the responding EuroSIDA clinics: half were univer-
sity clinics, almost half were government-affiliated, and
many were located in capital cities. Practices at these clinics
are therefore not necessarily representative of HIV manage-
ment in the European region overall.
Conclusions
Our study findings raise important questions about how
specific features of HIV clinics might contribute to the
geographical differences in patient outcomes in the
EuroSIDA study cohort. Significantly more East Europe
clinics deferred ART in asymptomatic patients until the
CD4 cell count dropped below 350 cells/mm3, and signifi-
cantly fewer East Europe clinics provided resistance test-
ing before initiating ART or upon ART failure. The East
Europe group of clinics also compared unfavourably to
the non-East Europe group in regard to HBV vaccination,
DAA access, TB/HIV treatment integration and screening
for cardiovascular disease, smoking, alcohol use and drug
use. There is a need for further research to guide setting-
specific decision-making regarding the optimal array of
services at HIV clinics in Europe and worldwide.
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